Francisco Batel Marques
Overview
Explore the profile of Francisco Batel Marques including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
252
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Luxi N, Ciccimarra F, Bellitto C, Raethke M, van Hunsel F, Lieber T, et al.
Vaccines (Basel)
. 2024 Sep;
12(9).
PMID: 39340089
Conventional vaccines rarely cause severe allergic reactions. However, the rapid development and approval of COVID-19 vaccines left limited initial data on their adverse reactions, particularly in individuals with a history...
2.
Ciccimarra F, Luxi N, Bellitto C, LAbbate L, Raethke M, van Hunsel F, et al.
Vaccines (Basel)
. 2024 Mar;
12(3).
PMID: 38543875
In all pivotal trials of COVID-19 vaccines, the history of previous SARS-CoV-2 infection was mentioned as one of the main exclusion criteria. In the absence of clinical trials, observational studies...
3.
Raethke M, van Hunsel F, Luxi N, Lieber T, Bellitto C, Mulder E, et al.
Vaccine
. 2024 Mar;
42(9):2357-2369.
PMID: 38448322
Introduction: During the COVID-19 pandemic, EMA set-up a large-scale cohort event monitoring (CEM) system to estimate incidence rates of patient-reported adverse drug reactions (ADRs) of different COVID-19 vaccines across the...
4.
Alves C, Penedones A, Mendes D, Marques F
Int J Clin Pharm
. 2023 Apr;
45(4):830-838.
PMID: 37074513
Background: Topical Janus kinase (JAK) inhibitors are being developed for the treatment of mild to moderate atopic dermatitis. However, comparative evidence on their safety profiles is still limited. Aim: This...
5.
Alves C, Penedones A, Mendes D, Marques F
Eur J Clin Pharmacol
. 2022 Oct;
78(12):1923-1933.
PMID: 36207461
Purpose: Janus kinase (JAK) inhibitors have been developed to treat moderate to severe atopic dermatitis, but there is little evidence comparing the safety profile of these drugs. The aim of...
6.
Alves C, Penedones A, Mendes D, Marques F
J Clin Rheumatol
. 2021 Nov;
28(2):69-76.
PMID: 34741000
Background/objective: The Janus kinases are cytoplasmic tyrosine kinases associated with membrane cytokine receptors that mediate signaling of multiple cytokines and growth factors, contributing to the pathogenesis of multiple autoimmune disorders....
7.
Alves C, Penedones A, Mendes D, Marques F
J Clin Rheumatol
. 2021 Apr;
28(2):e407-e414.
PMID: 33902098
Background/objective: The Janus kinases (JAKs) are cytoplasmic tyrosine kinases associated with membrane cytokine receptors that mediate signaling of multiple cytokines and growth factors, contributing to the pathogenesis of multiple autoimmune...
8.
Ribeiro I, Marques F, Mendes D, Alves C
Ophthalmic Epidemiol
. 2020 Jul;
27(5):325-338.
PMID: 32691652
Purpose: To characterize the techniques used to derive health-state utilities (HSU) in the cost-utility studies (CUS) of ophthalmic drugs. Methods: A systematic review was conducted in Pubmed/Embase until October 2019....
9.
Spontaneous reports of hypersensitivity adverse drug reactions in Portugal: a retrospective analysis
Mendes D, Oliveira A, Alves C, Marques F
Expert Opin Drug Saf
. 2020 Mar;
19(6):763-769.
PMID: 32167395
Background: Hypersensitivity adverse drug reactions (ADRs) are usually serious, unpredictable, and associated with high morbidity and mortality. This study describes cases of hypersensitivity ADRs spontaneously reported in Central Portugal. Methods:...
10.
Ribeiro I, Marques F, Alves D, Alves C
Acta Ophthalmol
. 2020 Feb;
98(3):237-243.
PMID: 32003153
Purpose: To characterize the effectiveness measures of cost-effectiveness studies (CES) of ophthalmic drugs. Methods: A systematic review was conducted in PubMed/Embase until October 2019. Cost-effectiveness studies (CES) evaluating ophthalmic drugs...